Alzheimer's Association International Cohort Study of Chronic Neurological Sequelae of SARS-CoV-2

Scientific leaders, including the Alzheimer's Association and representatives from more than 25 countries, are working together with technical guidance from the World Health Organization (WHO) to track the long-term impact of SARS-CoV-2 (also known as novel coronavirus, COVID-19) on the brain.

The impact of SARS-CoV-2 on the brain

The ongoing pandemic of SARS-CoV-2 has focused global health care resources on treating affected individuals and preventing the further spread of the infection. Although little is known about the long-term consequences of SARS-CoV-2 infection, there are several research studies to suggest that COVID-19 is associated with neurological complications. The downstream impact of COVID-19 on the brain is not well understood. There are many unanswered questions regarding the effects of SARS-CoV-2 on the cerebrovascular system (e.g., blood-brain barrier integrity), the brain's immune response and more.

Read the latest paper in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, "The chronic neuropsychiatric sequelae of COVID‐19: The need for a prospective study of viral impact on brain functioning," that surveys 100 years of data on major viral infections — including SARS, MERS and COVID — and their long-term impact on the brain.

About this study

Scientific leaders, including the Alzheimer’s Association and representatives from more than 25 countries — with technical guidance from the WHO — formed an international, multidisciplinary consortium to collect and evaluate the short- and long-term consequences of the viral infection on the central nervous system (CNS), as well as the differences across countries on the viral impact of COVID-19. This study aims to better understand the long-term consequences that may impact the brain, cognition and function — including underlying biology that may contribute to Alzheimer’s and other dementia.

This study will enroll two groups of individuals:

  • People with confirmed cases of COVID-19 from hospitals that have been discharged. They will be evaluated for follow up evaluations at 6, 9 and 18 months.
  • People who are enrolled in existing international research studies to add additional measures and markers of their underlying biology.

Contact for more information

To learn more about this study, please contact:

Heather Snyder, Ph.D.
Vice President, Medical and Scientific Relations
Alzheimer’s Association

Gabriel A. de Erausquin, M.D., Ph.D., MSc
Zachry Foundation Distinguished Professor of Neurology
Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases
Long School of Medicine
UT Health San Antonio

Sudha Seshadri, M.D.
Founding Director
Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases
Long School of Medicine
UT Health San Antonio

Traolach (Terry) Brugha, M.D., FRCPsych, SFHEA
Professor of Psychiatry, Social and Epidemiological Psychiatry Group,
Mental Health Aging Primary Care and Public Health (MAPP), Department of Health Sciences
College of Life Sciences
University of Leicester

Related initiatives